Is Hyperthermic Intraperitoneal Chemotherapy Appropriate for Colon Cancer?

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Colorectal cancer (CRC) with peritoneal metastases presents significant management challenges.
• Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers survival benefits in select patients at experienced centers.
• Current treatment paradigms for CRS/HIPEC in CRC are evolving.

Purpose of the Study:

• To review the current recommendations and emerging trends in hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastases.
• To evaluate the evidence supporting different chemotherapeutic agents and perfusion times in HIPEC for CRC.

Main Methods:

• Review of recent randomized controlled trials and clinical evidence.
• Analysis of current practices and emerging trends in CRS/HIPEC for colorectal cancer.

Main Results:

• HIPEC using oxaliplatin with shortened perfusion (30 minutes) after CRS is no longer recommended based on recent trials.
• There is a trend towards using mitomycin C with extended perfusion (90-120 minutes) as a first-line agent.
• Prospective evidence supporting the widespread use of mitomycin C in this setting is limited.

Conclusions:

• Management of colorectal cancer with peritoneal metastases requires careful patient selection and experienced centers for CRS/HIPEC.
• Oxaliplatin-based HIPEC with short perfusion is discouraged.
• Further prospective research is needed to validate the efficacy and safety of mitomycin C for extended perfusion HIPEC in CRC.